London, Ontario, Canada, 03 October, 2025 – KGK Science Inc., a leading North American contract research organization and regulatory consulting firm, is proud to announce the successful approval of a Class III Product License Application (PLA) for Qlarity™, a unique product developed by Lucid Psycheceuticals. This approval grants Qlarity™ its Natural Product Number (NPN), authorizing its sale in Canada.
The achievement marks the culmination of a long and unique regulatory journey that required specialized expertise and persistence. KGK Science’s regulatory team partnered closely with Lucid’s to navigate the complexities of Health Canada’s rigorous PLA process, ensuring compliance and securing market authorization for this innovative product.
Prior to the PLA submission, KGK provided comprehensive regulatory consulting to evaluate the regulatory status of Qlarity™’s ingredients, identify path-to-market strategies, and address data gaps required for entering the U.S. and Canadian markets. This strategic groundwork enabled a robust dossier submission and paved the way for the successful approval.
With over 28 years of experience, KGK Science continues to be a trusted partner for nutraceutical and natural health product companies, providing regulatory strategy, clinical trials, and preclinical services to help innovative products enter the North American markets with confidence.
About KGK Science
Founded in 1997, KGK Science is a premium contract research organization (CRO) offering clinical trial management, regulatory consulting, and preclinical expertise to support the natural health, nutraceutical, cannabis, hemp, psychedelic, and pharmaceutical industries. With a proven track record of regulatory successes and over 400 clinical trials conducted, KGK Science helps clients bring safe, effective, and compliant products to market.
About Lucid Psycheceuticals
Lucid Psycheceuticals is a dedicated team in pursuit of Total Brain Health™ and Pharmaceutically Green™ solutions. Founded with a mission to develop novel therapeutics for neurodegenerative diseases, inflammatory disorders, and mental health challenges, the company is rooted in world-class science supported by strong intellectual property and technology protection. By combining scientific excellence with a commitment to innovation and sustainability, Lucid Psycheceuticals is advancing groundbreaking treatments that aim to redefine the future of brain health and improve lives worldwide. Davis Comprehensive Cancer Center with a clinical and research interest in integrative oncology and women’s health.
